An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

Conditions

• Cancer

Interventions

• DRUG: Regimen A
• DRUG: Regimen B
• DRUG: Regimen C
• DRUG: Regimen D

Sponsor

GlaxoSmithKline